Burning Rock Narrows Losses, Eyes Growth with Key Patent Win

GUANGZHOU, China – March 12, 2026 – Burning Rock Biotech Limited (NASDAQ: BNR) has signaled a significant operational turnaround, reporting a dramatic reduction in net loss and improved financial health for the full year 2025. The precision oncology company's latest financial disclosure reveals that a strategic pivot towards higher-margin services, coupled with stringent cost controls, is yielding substantial results, while key innovations in its cancer detection pipeline gain crucial regulatory and intellectual property momentum in both China and the United States.

A Financial Turnaround Fueled by Strategy

Burning Rock's 2025 financial results paint a picture of a company regaining its footing through deliberate strategic realignment. The most striking figure is the sharp narrowing of its full-year net loss to RMB55.3 million (US$7.9 million), a stark improvement from the RMB346.6 million loss reported in 2024. This was achieved alongside a 4.6% increase in total annual revenues, which reached RMB539.6 million (US$77.2 million).

The improved bottom line was driven by a dual effort of boosting profitability and slashing expenses. The company's gross margin for 2025 climbed to 74.7%, up from 70.3% in the prior year. This margin expansion reflects a successful shift in revenue streams. Revenue from pharma research and development services surged by 34.5%, indicating strong demand from drug development partners. Concurrently, the in-hospital business, where Burning Rock helps establish and supply NGS labs directly within hospitals, remained stable and demonstrated improved gross margins of 74.4%.

This growth came as the company strategically scaled back its lower-margin central laboratory business, which saw an 8.9% decrease in revenue. This transition is a core component of the company's strategy to enhance profitability.

Underpinning the financial recovery was a rigorous campaign of operational efficiency. Total operating expenses for 2025 were cut by 36.4% to RMB457.8 million, down from RMB720.0 million in 2024. The company attributed these savings to comprehensive budget control measures, headcount reduction, and departmental reorganization, which affected research and development, sales and marketing, and general and administrative functions. The effort appears to be sustainable, with the company reporting positive operating cash flow of RMB23.0 million in the fourth quarter of 2025.

Innovation Pipeline Accelerates

While financial discipline was a major theme, Burning Rock also showcased significant progress in its product pipeline, reinforcing its position as an innovator in cancer diagnostics.

A landmark achievement came in January 2026 when the United States Patent and Trademark Office (USPTO) officially granted the core patent for ELSA-seq, the company's proprietary ultrasensitive cancer detection technology. This is the first U.S. patent for the technology, which is foundational to its early cancer detection and recurrence monitoring products. ELSA-seq powers the OverC® multi-cancer early detection test, which has already received Breakthrough Device Designation from both the U.S. FDA and China's NMPA, signaling its potential clinical significance.

Closer to home, the company's OncoScreen® BCMatch Tissue Kit officially entered the Priority Review Channel of China's Center for Medical Device Evaluation (CMDE). This accelerated pathway could speed up its market entry in the crucial domestic market.

Clinical validation for its products also continued to advance. In December 2025, study results published in the Annals of Surgery highlighted the effectiveness of its CanCatch® Custom test. The study demonstrated that the ctDNA-based test is strongly associated with recurrence in colorectal cancer patients and outperforms other methods in predicting disease-free survival. This adds to a growing body of evidence supporting the clinical utility of the company's minimal residual disease (MRD) monitoring technology.

Navigating China's Evolving Oncology Market

Burning Rock's strategy is deeply rooted in the unique dynamics of the Chinese healthcare market. As a domestic leader, it holds a significant market share in NGS-based cancer therapy selection but faces a competitive landscape that includes players like Genetron Health. The company’s focus on an in-hospital partnership model, where it has a commanding market share, appears well-suited to the local environment.

This approach aligns with China's broader national health initiatives, such as the "Healthy China 2030" plan, which prioritizes early diagnosis and advanced medical technology. Moreover, the NMPA has been actively streamlining its regulatory processes, creating accelerated approval pathways that benefit innovative companies like Burning Rock. The priority review for its OncoScreen® kit is a direct result of these favorable policies.

By embedding its technology directly within Chinese hospitals, Burning Rock not only generates recurring revenue from testing kits but also builds a deep, integrated network that is difficult for competitors to replicate. This localized strategy is crucial for navigating the complexities of the country's healthcare system.

Investor Outlook and Global Ambitions

For investors, Burning Rock's 2025 results present a compelling narrative of a company successfully executing a turnaround. The dramatic reduction in cash burn and the clear path toward profitability, driven by improved margins and cost controls, address key concerns that have previously weighed on the stock.

While the market's reaction to earnings has been mixed over the past year, the underlying operational improvements are undeniable. The combination of a fortified balance sheet and a disciplined operational model provides a stronger foundation for growth.

Furthermore, the company's ambitions clearly extend beyond China. The U.S. patent for ELSA-seq is a critical step for potential international commercialization, protecting its core technology in a major global market. This, combined with a 2025 approval in Japan for its OncoGuide™ OncoScreen™ Plus CDx System, developed with a local partner, demonstrates a multi-pronged approach to global expansion. The company's ability to leverage its newfound financial stability to fund these international ambitions, while continuing to consolidate its leadership in the vast Chinese market, will be the key storyline for investors to watch in the year ahead.